Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2025-12-25 @ 11:38 PM
NCT ID:
NCT01127893
Pre Assignment Details:
Due to the United States Food and Drug Administration (US FDA) imposed clinical hold, the study was terminated prematurely. Only 1 participant was enrolled and treated with tanezumab 2.5 mg treatment group and other planned treatments, tanezumab 5 or 10 mg, were not administered.
Recruitment Details:
Participants who had received tanezumab 2.5 milligram(mg) subcutaneously(SC) every 8 weeks, 5 mg SC every 8 weeks or 10 mg SC or intravenously every 8 weeks in parent Study A4091027 (NCT01089725) were to be assigned to same dose group and who received placebo in same parent study, were to be randomized to either tanezumab 2.5, 5 or 10 mg SC every 8 weeks in this study.
Study:
NCT01127893
Study Brief:
Results Section:
NCT01127893